10. Musculoskeletal system - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

BNF Section/s	Title	Issuing Body	Date of Issue	Update Due
10.1.3	Anakinra (Kineret®)	High-Cost Drugs
10.1.3	Anakinra (Kineret®) for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages [210701P] (1924)	NHS England	Nov 2021
10.1	Apremilast	High-Cost Drugs
10.1.3	Bimekizumab	High-Cost Drugs
10.1.3	Bimekizumab - Bimekizumab for treating axial spondyloarthritis TA918	NICE	Oct 2023
10.1.3	Bimekizumab - Bimekizumab for treating active psoriatic arthritis TA916	NICE	Oct 2023
10.2.2	Febuxostat - Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease	MHRA Drug Safety Update	May 2023	-
10.1.3	Filgotinib	High-Cost Drugs
10.1.3	Filgotinib - Filgotinib for treating moderate to severe rheumatoid arthritis TA676	NICE	Feb 2021	2024
10.2.2	Gout: diagnosis and management NICE guideline NG219	NICE	Jun 2022	-
10.1.3	Guselkumab	High-Cost Drugs	-	-
10.1.3	Guselkumab - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs TA815	NICE	Aug 2022	-
10.1.1	Hydroxychloroquine, chloroquine - increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions	MHRA Drug Safety Update	Feb 2022	-
10.1.3	Infliximab biosimilar (Flixabi®)	*High-Cost Drugs*
10.1.3	Infliximab biosimilar - Flixabi® Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA375 ICB commissioned - approval via Blueteq	NICE	Dec 2015
10.1.3	Infliximab biosimilar - Flixabi® Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA195 ICB commissioned - approval via Blueteq	NICE	Aug 2010
10.1.3	Infliximab biosimilar - Flixabi® Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed TA715 ICB commissioned - approval via Blueteq	NICE	Jul 2021
10.1.3	Infliximab biosimilar - Flixabi® Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA199 ICB commissioned - approval via Blueteq	NICE	Aug 2010
10.1.3	Infliximab biosimilar - Flixabi® TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis TA383 ICB commissioned - approval via Blueteq	NICE	Feb 2016
10.4	NSAIDS - Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy	MHRA Drug Safety Update	Jun 2023	-
10.3.3	Quinine - Safety Alert - Quinine not to be used routinely for nocturnal leg cramps	MHRA Drug Safety Update	Dec 2014	-
10.3.3	Quinine - Safety Alert - Quinine reminder of dose-dependent QT-prolonging effects; updated medicine interactions	MHRA Drug Safety Update	Nov 2017	-
10.1.3	Risankizumab	High-Cost Drugs	-	-
10.1.3	Risankizumab - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs TA803	NICE	Jul 2022	*2025*
10.1.3	Rituximab see High Cost Drugs Manual for all commissioning indications	*High-Cost Drugs*
10.1.3	Tocilizumab biosimilar Tyenne®	*High-Cost Drugs*
10.1.3	Tocilizumab biosimilar Tyenne® - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis NICE Guidance TA238 ICB commissioned - approval via Blueteq	NICE	Dec 2011
10.1.3	Tocilizumab biosimilar Tyenne® - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis NICE Guidance TA373 NHSE commissioned - Prior approval proforma required via Blueteq	NICE	Dec 2015
10.1.3	Tocilizumab biosimilar Tyenne® - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed NICE GuidanceTA375 ICB commissioned - approval via Blueteq	NICE	Jan 2016
10.1.3	Tofacitnib (Xeljanz®)	High-Cost Drugs	-	-
10.1.3	Tofacitnib - Tofacitinib for treating active ankylosing spondylitis TA920	NICE	Oct 2023	-
10.1.3	Upadacitinib	High-Cost Drugs	-	-
10.1.3	Upadacitinib - Upadacitinib for treating moderate rheumatoid arthritis TA744	NICE	Nov 2021	2024
10.1.3	Upadacitinib - Upadacitinib for treating active ankylosing spondylitis TA829	NICE	Sep 2022	-
10.1.3	Upadacitinib - Upadacitinib for treating active non-radiographic axial spondyloarthritis TA861	NICE	Feb 2023

First Line Choice
On Formulary
Specialist Initiation Only

Hospital Only
KMPT Initiation Only